EyePoint Pharmaceuticals, Inc. reported its financial results for the first quarter ending March 31, 2024, with total net revenue of $11.7 million, a significant increase from $7.7 million in the same period the previous year. The company experienced a decrease in net product revenue, attributed to the out-licensing of the YUTIQ franchise in May 2023, which marked a strategic shift from a commercial to a pipeline-focused biopharmaceutical company. Despite this, net revenue from royalties and collaborations surged to $11.0 million, primarily due to the recognition of deferred revenue from the YUTIQ license. Operating expenses rose to $45.0 million, driven by research and development costs for clinical trials and personnel expenses. The net loss for the quarter was $29.3 million, or ($0.55) per share. EyePoint's cash and...Show More

EyePoint Pharmaceuticals, Inc. reported its financial results for the first quarter ending March 31, 2024, with total net revenue of $11.7 million, a significant increase from $7.7 million in the same period the previous year. The company experienced a decrease in net product revenue, attributed to the out-licensing of the YUTIQ franchise in May 2023, which marked a strategic shift from a commercial to a pipeline-focused biopharmaceutical company. Despite this, net revenue from royalties and collaborations surged to $11.0 million, primarily due to the recognition of deferred revenue from the YUTIQ license. Operating expenses rose to $45.0 million, driven by research and development costs for clinical trials and personnel expenses. The net loss for the quarter was $29.3 million, or ($0.55) per share. EyePoint's cash and investments totaled $299.3 million, which is expected to fund operations through topline data for Phase 3 clinical trials of DURAVYU for wet AMD in 2026. The company also announced topline data from the Phase 2 PAVIA trial of DURAVYU in NPDR, which did not meet the primary endpoint but showed a favorable safety profile and biologic effect. Plans are underway to initiate the Phase 3 LUGANO trial for DURAVYU in wet AMD in the second half of 2024. EyePoint will host an R&D Day on June 26, 2024, to discuss its pipeline and technology.